Nipocalimab shows sustained disease control in adolescents with myasthenia gravis in Phase 2/3 study
Summary: Janssen-Cilag International NV announced positive results from the Phase 2/3 Vibrance-MG study of nipocalimab, the first FcRn blocker to show sustained disease control in adolescents aged 12-17 with generalized myasthenia gravis (gMG).
Participants receiving nipocalimab plus standard care achieved a 69% reduction in immunoglobulin G levels over 24 weeks. Four out of five patients showed minimal symptoms by the end of treatment, indicating significant clinical benefits.
These findings will be presented at the AANEM Annual Meeting in Savannah, Georgia. Nipocalimab is currently under review for approval by the European Medicines Agency and the U.S. Food and Drug Administration.
This is article metrics. Combined, they form a significance score, that indicates how important the news is on a scale from 0 to 10.
My algorithm scores 10,000 news articles daily, and creates a single significance-ordered list of news.
Read more about how I calculate significance, or see today's top ranked news on the main page:
See today's news rankings